EA201591050A1 - Имидазопиридиновые соединения - Google Patents
Имидазопиридиновые соединенияInfo
- Publication number
- EA201591050A1 EA201591050A1 EA201591050A EA201591050A EA201591050A1 EA 201591050 A1 EA201591050 A1 EA 201591050A1 EA 201591050 A EA201591050 A EA 201591050A EA 201591050 A EA201591050 A EA 201591050A EA 201591050 A1 EA201591050 A1 EA 201591050A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sgc
- cardiovascular diseases
- group
- hypertension
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
Задача. Представить фармацевтическую композицию для лечения или профилактики различных сердечно-сосудистых заболеваний, которая способна активировать sGC за счет улучшения передачи сигналов посредством cGMP. Средства решения. Было обнаружено, что имидазо[1,2-а]пиридиновые соединения, содержащие карбамоильную группу в 3-положении и конкретную циклическую группу в 8-положении через метиленоксигруппу, или их соли активируют sGC и применимы в качестве активных ингредиентов фармацевтических композиций для лечения или профилактики различных связанных с sGC сердечно-сосудистых заболеваний, в частности заболеваний периферических артерий, перемежающейся хромоты, критической ишемии конечностей, гипертензии и легочной гипертензии, оформив тем самым настоящее изобретение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012262962 | 2012-11-30 | ||
PCT/JP2013/082057 WO2014084312A1 (ja) | 2012-11-30 | 2013-11-28 | イミダゾピリジン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591050A1 true EA201591050A1 (ru) | 2016-04-29 |
EA027909B1 EA027909B1 (ru) | 2017-09-29 |
Family
ID=50827943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591050A EA027909B1 (ru) | 2012-11-30 | 2013-11-28 | Имидазопиридиновые соединения |
Country Status (19)
Country | Link |
---|---|
US (1) | US9278968B2 (ru) |
EP (1) | EP2927231B1 (ru) |
JP (1) | JP6056872B2 (ru) |
KR (1) | KR102093608B1 (ru) |
CN (1) | CN104822680B (ru) |
AU (1) | AU2013353117A1 (ru) |
BR (1) | BR112015012571B1 (ru) |
CA (1) | CA2891976C (ru) |
EA (1) | EA027909B1 (ru) |
ES (1) | ES2644611T3 (ru) |
HK (1) | HK1212984A1 (ru) |
IL (1) | IL238874A0 (ru) |
MX (1) | MX2015006856A (ru) |
PH (1) | PH12015501102B1 (ru) |
PL (1) | PL2927231T3 (ru) |
PT (1) | PT2927231T (ru) |
TW (1) | TW201439090A (ru) |
WO (1) | WO2014084312A1 (ru) |
ZA (1) | ZA201503794B (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
US8778964B2 (en) * | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
WO2015140199A1 (de) | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
WO2015165933A2 (de) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | 6-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
EP3180006A1 (de) * | 2014-08-14 | 2017-06-21 | Bayer Pharma Aktiengesellschaft | Substituierte chinolin-4-carboxamide und ihre verwendung |
JP2018505886A (ja) | 2015-02-05 | 2018-03-01 | バイエル・ファルマ・アクティエンゲゼルシャフト | 心血管疾患を治療するための可溶性グアニル酸シクラーゼ(SGC)の刺激物質としてのN−置換8−[(2,6−ジフルオロベンジル)オキシ]−2,6−ジメチルイミダゾ[1,2−a]ピラジン−3−カルボキサミド誘導体 |
JP2018505885A (ja) | 2015-02-05 | 2018-03-01 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ピラゾロ[1,5−a]−ピリジン−3−カルボキサミドおよびその使用 |
EA201792346A1 (ru) | 2015-05-06 | 2018-05-31 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
PE20181352A1 (es) * | 2015-09-17 | 2018-08-22 | Marvin J Miller | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias |
CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
CN110022871A (zh) | 2016-10-11 | 2019-07-16 | 拜耳制药股份公司 | 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品 |
US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
EP3554488A2 (en) | 2016-12-13 | 2019-10-23 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
EP3793553A1 (en) | 2018-05-15 | 2021-03-24 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
EP3820476A1 (en) | 2018-07-11 | 2021-05-19 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of mitochonrial disorders |
CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
US20220098134A1 (en) * | 2019-06-12 | 2022-03-31 | East China University Of Science And Technology | Antihypertensive polyol compound and derivative thereof |
CN113046754B (zh) * | 2019-12-28 | 2023-01-03 | 江苏苏博特新材料股份有限公司 | 一种苯并咪唑季铵盐钢筋缓蚀剂及其制备方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0266890A1 (en) * | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
JPH07242666A (ja) | 1994-03-08 | 1995-09-19 | Fujisawa Pharmaceut Co Ltd | 複素環化合物 |
SE9700661D0 (sv) * | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
WO1999063994A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE |
CA2319495A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
CA2318547A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Combinatorial synthesis of multibinding libraries |
AU4428899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of cyclooxygenase-2 |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
WO2001032604A1 (en) | 1999-11-05 | 2001-05-10 | University College London | Activators of soluble guanylate cyclase |
EP1277754B8 (en) * | 2000-04-27 | 2005-09-28 | Astellas Pharma Inc. | Imidazopyridine derivatives |
DE10021069A1 (de) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
CA2311483A1 (en) | 2000-06-12 | 2001-12-12 | Gregory N Beatch | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
US20040048866A1 (en) * | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
WO2003076408A2 (en) * | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
DE102006020327A1 (de) | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) * | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102006054757A1 (de) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
MX345762B (es) * | 2010-03-18 | 2017-02-15 | Pasteur Institut Korea | Compuestos antiinfecciosos. |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
US9365574B2 (en) * | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP2585055A1 (de) * | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
WO2012004259A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | Annellierte 4 -aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
KR20130132393A (ko) | 2010-07-09 | 2013-12-04 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 고리-융합된 피리미딘 및 트리아진, 및 심혈관 질환의 치료 및/또는 예방을 위한 그의 용도 |
DE102010031666A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Carbamat-substituierte Diaminopyrimidine und ihre Verwendung |
DE102010031667A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung |
DE102010031665A1 (de) | 2010-07-22 | 2012-01-26 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
US8569339B2 (en) * | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
ES2583086T3 (es) | 2011-04-21 | 2016-09-19 | Bayer Intellectual Property Gmbh | Pirazolopiridinas sustituidas con fluoroalquilo y su uso |
DE102011075398A1 (de) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituierte Imidazopyridazine und ihre Verwendung |
ES2592267T3 (es) | 2011-05-06 | 2016-11-29 | Bayer Intellectual Property Gmbh | Imidazopiridinas e imidazopiridazinas sustituidas y su uso |
CA2836202A1 (en) | 2011-05-30 | 2012-12-06 | Astellas Pharma Inc. | Imidazopyridine compounds |
WO2013004785A1 (de) | 2011-07-06 | 2013-01-10 | Bayer Intellectual Property Gmbh | Heteroaryl-substituierte pyrazolopyridine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
CN104039784B (zh) | 2011-09-02 | 2017-08-22 | 拜耳知识产权有限责任公司 | 取代的增环嘧啶及其用途 |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
-
2013
- 2013-11-28 TW TW102143539A patent/TW201439090A/zh unknown
- 2013-11-28 MX MX2015006856A patent/MX2015006856A/es active IP Right Grant
- 2013-11-28 PT PT138589924T patent/PT2927231T/pt unknown
- 2013-11-28 JP JP2014549894A patent/JP6056872B2/ja active Active
- 2013-11-28 KR KR1020157016680A patent/KR102093608B1/ko active IP Right Grant
- 2013-11-28 BR BR112015012571-9A patent/BR112015012571B1/pt active IP Right Grant
- 2013-11-28 CA CA2891976A patent/CA2891976C/en active Active
- 2013-11-28 PL PL13858992T patent/PL2927231T3/pl unknown
- 2013-11-28 US US14/428,798 patent/US9278968B2/en not_active Expired - Fee Related
- 2013-11-28 ES ES13858992.4T patent/ES2644611T3/es active Active
- 2013-11-28 WO PCT/JP2013/082057 patent/WO2014084312A1/ja active Application Filing
- 2013-11-28 EP EP13858992.4A patent/EP2927231B1/en active Active
- 2013-11-28 AU AU2013353117A patent/AU2013353117A1/en not_active Abandoned
- 2013-11-28 CN CN201380062525.1A patent/CN104822680B/zh active Active
- 2013-11-28 EA EA201591050A patent/EA027909B1/ru not_active IP Right Cessation
-
2015
- 2015-05-18 PH PH12015501102A patent/PH12015501102B1/en unknown
- 2015-05-18 IL IL238874A patent/IL238874A0/en unknown
- 2015-05-27 ZA ZA2015/03794A patent/ZA201503794B/en unknown
-
2016
- 2016-01-29 HK HK16101051.6A patent/HK1212984A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EA027909B1 (ru) | 2017-09-29 |
KR20150090157A (ko) | 2015-08-05 |
JP6056872B2 (ja) | 2017-01-11 |
EP2927231B1 (en) | 2017-09-20 |
CA2891976A1 (en) | 2014-06-05 |
PH12015501102A1 (en) | 2015-07-27 |
BR112015012571B1 (pt) | 2022-05-24 |
PL2927231T3 (pl) | 2018-01-31 |
US20150232464A1 (en) | 2015-08-20 |
CN104822680B (zh) | 2016-10-12 |
TW201439090A (zh) | 2014-10-16 |
MX2015006856A (es) | 2016-02-17 |
ZA201503794B (en) | 2016-11-30 |
CA2891976C (en) | 2020-07-21 |
HK1212984A1 (zh) | 2016-06-24 |
IL238874A0 (en) | 2015-07-30 |
PT2927231T (pt) | 2017-10-31 |
JPWO2014084312A1 (ja) | 2017-01-05 |
WO2014084312A1 (ja) | 2014-06-05 |
ES2644611T3 (es) | 2017-11-29 |
BR112015012571A2 (pt) | 2019-12-17 |
AU2013353117A1 (en) | 2015-06-04 |
US9278968B2 (en) | 2016-03-08 |
CN104822680A (zh) | 2015-08-05 |
EP2927231A1 (en) | 2015-10-07 |
EP2927231A4 (en) | 2016-04-20 |
PH12015501102B1 (en) | 2015-07-27 |
KR102093608B1 (ko) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591050A1 (ru) | Имидазопиридиновые соединения | |
NZ629996A (en) | 2’- substituted carba-nucleoside analogs for antiviral treatment | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
MX347596B (es) | Derivados de purina para el tratamiento de infecciones viricas. | |
MY170941A (en) | Pyrimidine derivatives for the treatment of viral infections | |
EA201590890A1 (ru) | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу | |
EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
WO2012118812A3 (en) | Substituted 6,5-fused bicyclic heteroaryl compounds | |
EA201490774A1 (ru) | Новые производные оксазина и их применение при лечении заболевания | |
EA201500448A1 (ru) | Гуанидиновое соединение | |
EA201490540A1 (ru) | Соединения и композиции в качестве ингибиторов с-kit киназы | |
EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
PH12015500724A1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201390826A1 (ru) | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA | |
MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
EA201590562A1 (ru) | Бензамиды | |
EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
EA201692544A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
EA201692496A1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии | |
EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
EA201301083A1 (ru) | Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |